Sterling Pharma Solutions
Matt Miklas is an experienced professional in the field of chemical engineering, currently serving as Associate Director of Technical Services at Sterling Pharma Solutions since October 2020. Prior to this role, Matt held various positions at Alcami Corporation, including Senior Technical Manager and Technical Manager, from September 2015 to October 2020. Matt began his career at Cambridge Major Laboratories as a Process Engineer and previously worked at Bemis Company, Inc. as a Product Development Engineer. Academic training includes a Bachelor of Science in Chemical Engineering from the University of Wisconsin-Madison, where involvement also included serving as Head Tutor and conducting research on Alzheimer's Disease. Matt has also gained experience as a Research and Development Intern at Ecolab.
This person is not in any teams
This person is not in any offices
Sterling Pharma Solutions
1 followers
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities